Formycon has recently seen positive uptake trends for its FYB201 biosimilar rival to Lucentis (ranibizumab) in both the US and UK, according to the latest figures revealed by the German developer.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?